US 11,971,411 B2
Compositions and methods for screening and identifying clinically aggressive prostate cancer
Curtis Huttenhower, Boston, MA (US); Travis Gerke, Tampa, FL (US); Christopher Sweeney, Waban, MA (US); Lorelei Mucci, Newton, MA (US); Gwo-Sho Mary Lee, Newton, MA (US); Daniela Bornigen, Tostedt (DE); Xiaodong Wang, Stoughton, MA (US); Svitlana Tyekucheva, Boston, MA (US); and Kristina Jordahl, Seattle, WA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Appl. No. 16/071,289
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
PCT Filed Jan. 20, 2017, PCT No. PCT/US2017/014362
§ 371(c)(1), (2) Date Jul. 19, 2018,
PCT Pub. No. WO2017/127696, PCT Pub. Date Jul. 27, 2017.
Claims priority of provisional application 62/280,994, filed on Jan. 20, 2016.
Prior Publication US 2020/0041515 A1, Feb. 6, 2020
Int. Cl. C12Q 1/68 (2018.01); G01N 33/574 (2006.01)
CPC G01N 33/57434 (2013.01) [G01N 2333/4703 (2013.01); G01N 2800/54 (2013.01); G01N 2800/56 (2013.01)] 12 Claims
 
1. A method of measuring the expression level of ZFP36 and PTEN in a subject having prostate cancer, the method consisting of:
a. measuring the binding of a first probe in a first sample from the subject, wherein the first probe specifically hybridizes to a nucleic acid having the sequence set forth in SEQ ID NO: 2, thereby measuring expression of ZFP36 in the subject, and
b. measuring the binding of a second probe in a second sample from the subject, wherein the second probe specifically hybridizes to a nucleic acid having the sequence set forth in SEQ ID NO: 15, 16, or 17, thereby measuring expression of PTEN in the subject.